127 related articles for article (PubMed ID: 9477121)
21. Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
Varadi G; Ackerstein A; Ben-Neriah S; Nagler A
Bone Marrow Transplant; 1998 Jan; 21(1):93-6. PubMed ID: 9486502
[TBL] [Abstract][Full Text] [Related]
22. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.
Bhatia R; McGlave PB
Leukemia; 1995 Jun; 9(6):1006-12. PubMed ID: 7596165
[TBL] [Abstract][Full Text] [Related]
23. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
24. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
[TBL] [Abstract][Full Text] [Related]
25. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
26. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
27. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
28. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
Cervantes F; Miller JS; McGlave PB
Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
[TBL] [Abstract][Full Text] [Related]
29. [NK cells: a major role in the antitumoral immunomodulation in CML].
Toubert A; Turhan A; Guerci-Bresler A; Dulphy N; Réa D
Med Sci (Paris); 2018; 34(6-7):540-546. PubMed ID: 30067206
[TBL] [Abstract][Full Text] [Related]
30. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
[TBL] [Abstract][Full Text] [Related]
31. [In vitro induction of autologous T cell killing by heat treated human chronic myelogenous leukemia cells].
He X; You S; Bian S; Liao X; Li M; Ma S; Ge W; Qian L
Zhonghua Xue Ye Xue Za Zhi; 2000 Jun; 21(6):287-90. PubMed ID: 11876993
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
34. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
35. Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
Mackinnon S; Bungey J; Chase A; Paulsen W; Hows JM; Goldman JM
Br J Haematol; 1991 Jan; 77(1):60-5. PubMed ID: 1998598
[TBL] [Abstract][Full Text] [Related]
36. The role of FAS-mediated apoptosis in chronic myelogenous leukemia.
Selleri C; Maciejewski JP
Leuk Lymphoma; 2000 Apr; 37(3-4):283-97. PubMed ID: 10752980
[TBL] [Abstract][Full Text] [Related]
37. Role of cancer immunology in chronic myelogenous leukemia.
Ureshino H; Shindo T; Kimura S
Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
[TBL] [Abstract][Full Text] [Related]
38. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
[TBL] [Abstract][Full Text] [Related]
39. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
40. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
Estrov Z; Kurzrock R; Talpaz M
Leuk Lymphoma; 1993 Aug; 10(6):407-18. PubMed ID: 8401177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
